MX364859B - Derivados de imidazopirazinona. - Google Patents

Derivados de imidazopirazinona.

Info

Publication number
MX364859B
MX364859B MX2016008042A MX2016008042A MX364859B MX 364859 B MX364859 B MX 364859B MX 2016008042 A MX2016008042 A MX 2016008042A MX 2016008042 A MX2016008042 A MX 2016008042A MX 364859 B MX364859 B MX 364859B
Authority
MX
Mexico
Prior art keywords
imidazopyrazinone
derivatives
diseases
imidazopyrazinone derivatives
tankyrase
Prior art date
Application number
MX2016008042A
Other languages
English (en)
Other versions
MX2016008042A (es
Inventor
Dorsch Dieter
Buchstaller Hans-Peter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2016008042A publication Critical patent/MX2016008042A/es
Publication of MX364859B publication Critical patent/MX364859B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Abstract

Se describen compuestos de la fórmula I (ver Fórmula) en los cual R1 y R2 tienen los significados indicados en la reivindicación 1, que son inhibidores de tanquirasas, y se pueden emplear, inter alia, para el tratamiento de enfermedades tal como cáncer, enfermedades cardiovasculares, lesión del sistema nervioso central y diferentes formas de inflamación.
MX2016008042A 2013-12-23 2014-12-03 Derivados de imidazopirazinona. MX364859B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13006052 2013-12-23
PCT/EP2014/003226 WO2015096884A1 (en) 2013-12-23 2014-12-03 Imidazopyrazinone derivatives

Publications (2)

Publication Number Publication Date
MX2016008042A MX2016008042A (es) 2016-09-16
MX364859B true MX364859B (es) 2019-05-09

Family

ID=49916790

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008042A MX364859B (es) 2013-12-23 2014-12-03 Derivados de imidazopirazinona.

Country Status (23)

Country Link
US (1) US9718826B2 (es)
EP (1) EP3087076B1 (es)
JP (1) JP6446461B2 (es)
KR (1) KR20160101188A (es)
CN (1) CN105829317B (es)
AU (1) AU2014372896B2 (es)
CA (1) CA2934663A1 (es)
DK (1) DK3087076T3 (es)
ES (1) ES2654403T3 (es)
HR (1) HRP20171783T1 (es)
HU (1) HUE037606T2 (es)
IL (1) IL246406A0 (es)
LT (1) LT3087076T (es)
MX (1) MX364859B (es)
NO (1) NO3087076T3 (es)
PL (1) PL3087076T3 (es)
PT (1) PT3087076T (es)
RS (1) RS56746B1 (es)
RU (1) RU2672885C2 (es)
SG (1) SG11201605189YA (es)
SI (1) SI3087076T1 (es)
TW (1) TWI637956B (es)
WO (1) WO2015096884A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN108403697A (zh) * 2018-05-02 2018-08-17 吉林大学 吡嗪酮类小分子抑制剂在制备抗肿瘤药物中的应用
IL281212B2 (en) * 2018-09-07 2023-12-01 Merck Patent Gmbh The history of 5-morpholine-4-yl-pyrazolo[[4,3-Bpyridine and their use
JP7433403B1 (ja) 2022-12-06 2024-02-19 本田技研工業株式会社 内燃機関及び鞍乗型車両

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005089352A (ja) 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
CN101468988A (zh) * 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
CN104169284B (zh) * 2012-03-28 2017-03-29 默克专利股份公司 双环吡嗪酮衍生物
MX357502B (es) * 2012-05-04 2018-07-12 Merck Patent Gmbh Derivados de pirrolotriazinona.

Also Published As

Publication number Publication date
US9718826B2 (en) 2017-08-01
CN105829317A (zh) 2016-08-03
MX2016008042A (es) 2016-09-16
RU2016130148A (ru) 2018-01-30
JP2017500353A (ja) 2017-01-05
HRP20171783T1 (hr) 2017-12-29
ES2654403T3 (es) 2018-02-13
US20170002010A1 (en) 2017-01-05
SI3087076T1 (en) 2018-01-31
WO2015096884A1 (en) 2015-07-02
HUE037606T2 (hu) 2018-09-28
TW201605862A (zh) 2016-02-16
RS56746B1 (sr) 2018-03-30
CN105829317B (zh) 2019-03-29
DK3087076T3 (da) 2017-11-13
AU2014372896A1 (en) 2016-08-04
AU2014372896B2 (en) 2018-08-16
PL3087076T3 (pl) 2018-01-31
KR20160101188A (ko) 2016-08-24
PT3087076T (pt) 2018-01-03
CA2934663A1 (en) 2015-07-02
NO3087076T3 (es) 2018-02-24
RU2016130148A3 (es) 2018-07-25
SG11201605189YA (en) 2016-07-28
JP6446461B2 (ja) 2018-12-26
LT3087076T (lt) 2017-12-27
TWI637956B (zh) 2018-10-11
EP3087076B1 (en) 2017-09-27
EP3087076A1 (en) 2016-11-02
IL246406A0 (en) 2016-08-31
RU2672885C2 (ru) 2018-11-20

Similar Documents

Publication Publication Date Title
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX362939B (es) Derivados de (aza-)isoquinolinona.
MX357502B (es) Derivados de pirrolotriazinona.
MX2016001136A (es) Derivados de oxoquinazolinil-butanamida.
PH12014501581A1 (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
NZ720478A (en) Autotaxin inhibitor compounds
PH12016500024A1 (en) Bromodomain inhibitor
MX2016014436A (es) Derivados de heterociclil-butanamida.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2016008042A (es) Derivados de imidazopirazinona.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2016001134A (es) Derivados 1,3-disustituidos de ciclopentano.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
MX2016001536A (es) Derivados de urea de piperidinas.
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
MX369393B (es) Derivados de ftalazina.
MX2016001934A (es) Derivados de ciclopentilamina 3-sustituidos.
PH12020500472A1 (en) Autotaxin inhibitor compounds

Legal Events

Date Code Title Description
FG Grant or registration